eversyn Secures €1.6M in Seed Funding to Advance Biotech Innovation in Nutrition and Biopharma 

Magdeburg, March 20, 2025 – The biotechnology startup eversyn, a spin-off from the Max Planck Institute for Dynamics of Complex Technical Systems, has raised €1.6 million in seed funding to scale production and accelerate its breakthrough technology for applications in the nutrition and biopharmaceutical sectors. 

The early-stage funding round, led by bmp Ventures with funds from the IBG, also included co-investments from the Max Planck Society, MPF Start-up Accelerator GmbH, and a strategic business angel. It follows a previously awarded €1.1 million EXIST Transfer of Research grant from Germany’s Federal Ministry for Economic Affairs and Climate Action (BMWK). 

eversyn is currently participating in the Startup Elevator Saxony-Anhalt Business Accelerator, which supports promising deep-tech startups from research to market. 

Unlocking Access to High-Value Glycans with Cell-Free Biosynthesis 

The startup’s cell-free enzymatic platform is designed to bypass limitations of traditional cell-based synthesis. This enables the efficient, flexible production of complex glycans, which play a critical role in developing next-generation therapeutics and functional food ingredients. 

“This funding round marks a pivotal moment for eversyn,” says Dr. Thomas Rexer, CEO and Co-Founder. “We now have the resources to scale our operations and bring our transformative technology closer to market. We’re committed to creating real value in global health by enabling novel solutions for nutrition and biopharma.” 

Strong Support from Investors and the Max Planck Innovation Ecosystem 

eversyn’s technology attracted backing from both financial and scientific institutions: 

Philipp Kopp, Investment Manager at bmp Ventures: 

“eversyn addresses key industry challenges with a scalable biotech platform and outstanding technical expertise. Their strategic approach to commercialization convinced us to invest.” 

Dr. Axel Nemetz, Managing Director of MPF Start-up Accelerator: 

“eversyn’s enzyme-based synthesis dramatically reduces production costs of glycans—by nearly an order of magnitude. This opens the door to scalable solutions in therapeutic development and human milk oligosaccharides. It’s a perfect match for our mission to support science-driven companies with global impact.” 

Max Planck Innovation—the technology transfer arm of the Max Planck Society—has supported eversyn from its IP strategy to this successful funding round. 

“eversyn is a model case of turning cutting-edge research into a viable business,” said Dr. Lars Cuypers and Sebastian Meyer-Borchert of Max Planck Innovation. 

From Research to Real-World Impact 

eversyn originated from years of scientific research at the Max Planck Institute in Magdeburg, which is renowned for its work in process systems engineering. The institute explores how complex systems—from chemical plants to biological cells—can be modeled, optimized, and scaled. 

With the new capital, eversyn plans to: 

• Expand its production capabilities 
• Grow its expert team 
• Accelerate R&D 
• Forge strategic partnerships 

These steps will position eversyn as a leading innovator in enabling high-performance, glycan-based solutions to address pressing health challenges worldwide. 

Pioneering the Future of Biotech in Saxony-Anhalt 

As part of the Startup Elevator Saxony-Anhalt accelerator, eversyn exemplifies how scientific excellence meets entrepreneurial vision. The team’s success story highlights the importance of research commercialization, strong ecosystems, and targeted support programs like EXIST and IBG-backed seed funding in turning breakthroughs into market-ready solutions. 

Follow the journey of eversyn and other deep-tech innovators at Startup Elevator Saxony-Anhalt.